ES2320525T3 - Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. - Google Patents
Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. Download PDFInfo
- Publication number
- ES2320525T3 ES2320525T3 ES00978215T ES00978215T ES2320525T3 ES 2320525 T3 ES2320525 T3 ES 2320525T3 ES 00978215 T ES00978215 T ES 00978215T ES 00978215 T ES00978215 T ES 00978215T ES 2320525 T3 ES2320525 T3 ES 2320525T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- alkyl
- alkylamino
- optionally substituted
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 12
- 125000004429 atom Chemical group 0.000 abstract 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- -1 amino, amino Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40760099A | 1999-09-28 | 1999-09-28 | |
| US407600 | 1999-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2320525T3 true ES2320525T3 (es) | 2009-05-25 |
Family
ID=23612752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00978215T Expired - Lifetime ES2320525T3 (es) | 1999-09-28 | 2000-09-26 | Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. |
Country Status (35)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001279938B2 (en) * | 2000-08-09 | 2007-01-25 | Astrazeneca Ab | Indole, azaindole and indazole derivatives having VEGF inhibiting activity |
| CN1308310C (zh) | 2000-10-20 | 2007-04-04 | 卫材R&D管理有限公司 | 含氮芳环衍生物 |
| JP2006503796A (ja) * | 2001-12-21 | 2006-02-02 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法 |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| MXPA05009687A (es) * | 2003-03-11 | 2005-10-20 | Novartis Ag | Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map. |
| WO2004089412A1 (ja) * | 2003-04-08 | 2004-10-21 | Mitsubishi Pharma Corporation | 特異的ｎａｄ(ｐ)ｈオキシダーゼ抑制剤 |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| KR100553398B1 (ko) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| CA2579810C (en) | 2004-09-17 | 2012-01-24 | Eisai R&D Management Co., Ltd. | Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| US8304406B2 (en) | 2006-04-15 | 2012-11-06 | Bayer Intellectual Property Gmbh | Compounds for treating pulmonary hypertension |
| US20090209580A1 (en) | 2006-05-18 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
| US20120077842A1 (en) | 2009-08-19 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| JP5898074B2 (ja) | 2010-06-25 | 2016-04-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| EP2937337A4 (en) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| CN103396361B (zh) * | 2013-07-24 | 2016-05-04 | 中国人民解放军第二军医大学 | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| WO2016136745A1 (ja) | 2015-02-25 | 2016-09-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| CN104804008B (zh) * | 2015-03-27 | 2016-03-23 | 亿腾药业（泰州）有限公司 | 一种工业化生产甲磺酸特拉替尼的方法 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| EP3338779B1 (en) | 2015-08-20 | 2021-06-30 | Eisai R&D Management Co., Ltd. | Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor |
| AU2018219637B2 (en) | 2017-02-08 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN107129502B (zh) * | 2017-04-13 | 2022-08-05 | 泰州亿腾景昂药业股份有限公司 | EOC315 Mod.I晶型化合物及其制备方法 |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
| WO2020219448A1 (en) * | 2019-04-22 | 2020-10-29 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| CN112830932B (zh) * | 2020-12-25 | 2022-04-08 | 泰州亿腾景昂药业股份有限公司 | 特拉替尼的游离碱晶型及其制备方法与用途 |
| IL312506A (en) | 2021-11-08 | 2024-07-01 | Progentos Therapeutics Inc | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453897A (fr) * | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| GB1094044A (en) * | 1965-07-12 | 1967-12-06 | Vantorex Ltd | Phthalazine derivatives |
| FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| US5849741A (en) * | 1994-08-09 | 1998-12-15 | Eisai Co., Ltd. | Fused pyridazine compounds |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| DE69942097D1 (de) * | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| EP1165085B1 (en) * | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| EP1254138B1 (en) * | 2000-02-09 | 2005-05-11 | Novartis AG | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
-
2000
- 2000-09-22 AR ARP000104981A patent/AR025752A1/es not_active Application Discontinuation
- 2000-09-22 CO CO00072226A patent/CO5200835A1/es active IP Right Grant
- 2000-09-22 GT GT200000158A patent/GT200000158A/es unknown
- 2000-09-22 DO DO2000000070A patent/DOP2000000070A/es unknown
- 2000-09-25 MY MYPI20051064A patent/MY143377A/en unknown
- 2000-09-25 PA PA20008503201A patent/PA8503201A1/es unknown
- 2000-09-25 MY MYPI20004467A patent/MY135058A/en unknown
- 2000-09-25 TW TW089119700A patent/TW593315B/zh not_active IP Right Cessation
- 2000-09-25 PE PE2000001004A patent/PE20010607A1/es not_active Application Discontinuation
- 2000-09-25 MY MYPI20051063A patent/MY143580A/en unknown
- 2000-09-26 UA UA2002043504A patent/UA75053C2/uk unknown
- 2000-09-26 CN CNB2005101271092A patent/CN100422172C/zh not_active Expired - Lifetime
- 2000-09-26 IL IL14888000A patent/IL148880A0/xx active IP Right Grant
- 2000-09-26 EE EEP200200161A patent/EE05258B1/xx not_active IP Right Cessation
- 2000-09-26 KR KR1020087021379A patent/KR100895571B1/ko not_active Expired - Lifetime
- 2000-09-26 CA CA2385817A patent/CA2385817C/en not_active Expired - Lifetime
- 2000-09-26 BR BRPI0014382A patent/BRPI0014382B8/pt not_active IP Right Cessation
- 2000-09-26 HR HR20020308A patent/HRP20020308A2/xx not_active IP Right Cessation
- 2000-09-26 AT AT00978215T patent/ATE422494T1/de not_active IP Right Cessation
- 2000-09-26 CN CNB2005101271105A patent/CN100422173C/zh not_active Expired - Lifetime
- 2000-09-26 WO PCT/US2000/026500 patent/WO2001023375A2/en not_active Ceased
- 2000-09-26 HU HU0202704A patent/HU230223B1/hu not_active IP Right Cessation
- 2000-09-26 KR KR1020027003972A patent/KR100890473B1/ko not_active Expired - Lifetime
- 2000-09-26 RS YUP-229/02A patent/RS50369B/sr unknown
- 2000-09-26 KR KR1020087021380A patent/KR100895572B1/ko not_active Expired - Lifetime
- 2000-09-26 AU AU15696/01A patent/AU782820B2/en not_active Expired
- 2000-09-26 CN CNB008163693A patent/CN100374435C/zh not_active Expired - Lifetime
- 2000-09-26 MX MXPA02003156A patent/MXPA02003156A/es active IP Right Grant
- 2000-09-26 SK SK591-2002A patent/SK287417B6/sk not_active IP Right Cessation
- 2000-09-26 PL PL366342A patent/PL205957B1/pl unknown
- 2000-09-26 NZ NZ518589A patent/NZ518589A/en not_active IP Right Cessation
- 2000-09-26 RU RU2002111414/04A patent/RU2260008C2/ru active
- 2000-09-26 EP EP00978215A patent/EP1228063B1/en not_active Expired - Lifetime
- 2000-09-26 JP JP2001526527A patent/JP4919567B2/ja not_active Expired - Lifetime
- 2000-09-26 DE DE60041548T patent/DE60041548D1/de not_active Expired - Lifetime
- 2000-09-26 ES ES00978215T patent/ES2320525T3/es not_active Expired - Lifetime
- 2000-09-26 CZ CZ2002-1444A patent/CZ304767B6/cs not_active IP Right Cessation
-
2002
- 2002-03-26 NO NO20021520A patent/NO20021520L/no unknown
- 2002-04-09 ZA ZA200202760A patent/ZA200202760B/xx unknown
- 2002-04-23 BG BG106637A patent/BG65860B1/bg unknown
- 2002-04-26 MA MA26619A patent/MA25563A1/fr unknown
-
2008
- 2008-08-11 IL IL193368A patent/IL193368A/en active IP Right Grant
- 2008-08-11 IL IL193367A patent/IL193367A/en active IP Right Grant
-
2011
- 2011-07-15 AR ARP110102559A patent/AR082232A2/es unknown
- 2011-07-15 AR ARP110102558A patent/AR082231A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2320525T3 (es) | Piridinas y piridazinas sustituidas con actividad inhibidora de la angiogenesis. | |
| RU2002111414A (ru) | Замещенные пиридины и пиридазины, обладающие способностью ингибировать ангиогенез | |
| WO2001092255A3 (en) | Epothilone derivatives and methods for making and using the same | |
| PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
| PE20010815A1 (es) | Uso de inhibidores de 3`,5'-guanosinmonofosfato ciclico fosfodiesterasa para el tratamiento de la hipertension pulmonar | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
| YU11299A (sh) | Derivati indazola | |
| LU90283I2 (fr) | Sporanox soluté buvable et ses dérivés pharmaceutiquement acceptables | |
| DE69705819D1 (de) | Angiogenesis hemmende pyridazinamine | |
| AR100696A2 (es) | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas | |
| AR005706A1 (es) | Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico | |
| DK1492526T3 (da) | Konjugerede prodrugs af CC-1065-analoger | |
| AR060431A1 (es) | Compuestos para el tratamiento de la hipertension pulmonar | |
| PE20220764A1 (es) | Conjugados de anticuerpo y farmaco | |
| DK1365808T3 (da) | Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743 | |
| GB1314903A (en) | Quinazoline derivatives | |
| BG100016A (bg) | Нiv протеазни инхибитори във фармацевтични комбинации за лечение на спин | |
| DK1237584T3 (da) | Receptorbindende konjugater | |
| SG165991A1 (en) | Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives | |
| AR025068A1 (es) | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis | |
| LT2001078A (en) | Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments | |
| EA200100716A1 (ru) | Способ профилактики рака молочной железы | |
| AU2003207432A1 (en) | Urea linker derivatives for use as ppar modulators | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen |